TP53 and breast carcinoma: Gonzalez and colleagues estimated the frequency of TP53 germline mutations in the general population using the frequency of specific cancers (breast cancer age ≤ 30 years and adrenocortical carcinoma) in the general population and the frequency of that cancer being due to TP53 germline mutations.